Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients.

MLA

Marcel Hoppentocht, et al. “Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients.” PLoS ONE, vol. 11, no. 3, Jan. 2016, p. e0149768. EBSCOhost, https://doi.org/10.1371/journal.pone.0149768.

APA

Marcel Hoppentocht, Onno W Akkerman, Paul Hagedoorn, Jan-Willem C Alffenaar, Tjip S van der Werf, Huib A M Kerstjens, Henderik W Frijlink, & Anne H de Boer. (2016). Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients. PLoS ONE, 11(3), e0149768. https://doi.org/10.1371/journal.pone.0149768

Chicago

Marcel Hoppentocht, Onno W Akkerman, Paul Hagedoorn, Jan-Willem C Alffenaar, Tjip S van der Werf, Huib A M Kerstjens, Henderik W Frijlink, and Anne H de Boer. 2016. “Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients.” PLoS ONE 11 (3): e0149768. doi:10.1371/journal.pone.0149768.